On 1 August 2024, the PBS published its Summary of Changes, which included listing Pfizer’s Abrilada®, biosimilar to AbbVie’s Humira® (adalimumab), on the PBS in 20mg/0.4mL and 40mg/0.8mL dosage injections.
This comes three years after Abrilada was first recommended or listing in July 2021 by Australia’s Pharmaceutical Benefits Advisory Council; required documentation was not submitted by Pfizer until February this year. Abrilada was first approved by the TGA in March 2021, being indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, as well as Crohn’s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa and uveitis.